Use of cookies
Cookies help us to provide our services. By using our website you agree that we can use cookies. Read more about our Privacy Policy and visit the following link: Privacy Policy (only in German)
2018.02.09
Active substance: obeticholic acid
Due to the risk of serious liver injury in patients with moderate and severe hepatic impairment, all patients are to be monitored by way of laboratory and clinical assessment for progression of the PBC disease during treatment with obeticholic acid in order to determine whether dosage adjustment is needed.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN